수술 후 통증 관리 : 시장 인사이트, 역학 및 예측(2036년)

Postoperative Pain Management Insights and Trends

• According to DelveInsight's analysis, Postoperative pain management market size was found to be ~USD 1,100 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Postoperative pain management follows a multimodal approach, combining pharmacological (opioids, NSAIDs, acetaminophen, anesthetics, adjuncts) and non-pharmacological therapies (acupuncture, physical therapy, CBT, TENS) to improve outcomes and reduce reliance on single interventions.
• There is a significant shift away from opioid-based therapy toward multimodal analgesia (MMA), driven by safety concerns, side effects, and initiatives from organizations such as the US Department of Health and Human Services (USDHHS).
• NSAIDs, while effective, are associated with gastrointestinal, renal, and cardiovascular risks, highlighting the need for cautious use and patient monitoring.
• The current postoperative pain market includes therapies such as JOURNAVX (suzetrigine), COMBOGESIC IV/MAXIGESIC IV, and ZYNRELEF, alongside established corticosteroids in postoperative inflammation and pain management.
• Several therapies have been discontinued or faced limited adoption (e.g., DSUVIA, OLINVYK, SEGLENTIS), reflecting safety, regulatory, and market access challenges in the acute pain landscape.
• There is a lack of effective parenteral non-opioid options, with limited approved therapies and discontinued commercialization of some agents despite clinical benefits.
• Emerging therapies and pipeline assets (e.g., ATX101, LTG-001, TRN-228) are expected to transform the treatment landscape, offering novel mechanisms and improved pain control.
• The acute pain market is projected to grow significantly, driven by increasing demand for non-opioid therapies, rising surgical volumes, and advancements in drug development and delivery systems.

Postoperative Pain Management Market Size and Forecast in the 7MM

• 2025 Postoperative Pain Market Size: ~USD 1,100 million
• 2036 Projected postoperative pain management Market Size: ~USD 9,000 million
• Postoperative pain management Growth Rate (2026-2036): ~12% CAGR

DelveInsight's 'Postoperative pain management - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Postoperative pain management, historical and forecasted epidemiology, as well as the Postoperative pain management market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Postoperative pain management market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, Postoperative pain management patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Postoperative pain management and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Postoperative Pain Management Market

• Rising Surgical Volume and Aging Population

The increasing number of surgical procedures globally, particularly among the aging population, is a major driver of postoperative pain management demand. Higher prevalence of chronic conditions and greater access to surgical care have significantly increased the need for effective postoperative pain control.

• Shift Toward Multimodal and Opioid-Sparing Approaches

Growing concerns around opioid-related adverse effects, dependency, and misuse have accelerated the transition toward multimodal analgesia (MMA). Clinical guidelines increasingly recommend combining non-opioid pharmacologic agents, regional anesthesia, and non-pharmacologic therapies to improve efficacy and safety.

• Rising Demand for Non-Opioid Therapies

There is a strong push for non-opioid analgesics, driven by safety concerns and evidence of opioid overprescription and underutilization. This has led to increased adoption of NSAIDs, acetaminophen, and novel agents, as well as continued investment in safer alternatives.

Postoperative Pain Management Understanding and Treatment Algorithm

Postoperative Pain Overview and Diagnosis

Effective postoperative pain control is critical to minimizing the adverse effects of acute postsurgical pain and promoting functional recovery. While opioids have traditionally been the mainstay of treatment, escalating rates of misuse and related mortality have driven a shift toward multimodal analgesia. These strategies aim to reduce opioid reliance but face challenges due to the subjective nature of pain and variability in patient response. Factors such as comorbidities, mental health, and social determinants can amplify pain perception, complicating standardized approaches.

Doctors diagnose the pain by discussing one's symptoms, the intensity and location of pain, and the history of injury, surgery, or illness. Young patients may be asked to rate their pain intensity using the faces of the pain scale.

Additional diagnostic tests might include:

• Blood tests
• x-rays
• CT scans
• MRI
• Ultrasounds
• Dye-injection studies
• Nerve conduction studies

Current Postoperative Pain Management Treatment Landscape

Postoperative pain management begins immediately after surgery and is tailored to patient and procedure factors. Effective management relies on specialist assessment, validated pain scales, and a multidisciplinary approach combining pharmacologic therapies such as NSAIDs, opioids, acetaminophen, and adjuncts like gabapentin with regional anesthesia and non-pharmacologic interventions like acupuncture or TENS. Continuous monitoring and adjustment of the pain plan are essential to ensure patient comfort, support functional recovery, and optimize postoperative outcomes.

Postoperative Pain Management Unmet Needs

The section "unmet needs of Postoperative Pain Management" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limitations associated with current treatments

2. Limited healthcare pain awareness

3. Patient compliance challenges

4. Patient-physician communication,and others.....

Postoperative Pain Management Epidemiology

Key Findings from Postoperative Pain Management Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, in 2025, the total number of incident cases of Postoperative Pain in the 7MM were ~89,900,000
• According to data from the Centers for Disease Control and Prevention (CDC), (2025) Emergency Department Visits, there were 40 million injury-related visits (including poisoning and adverse effects) in 2020. When adjusted for the 2020 population, this accounted for approximately 12.03%.
• In Germany, data from Destatis Statistisches Bundesamt (2025) indicated that ~16,500,000 surgeries were performed in 2023.
• A study reported in US and Japan for postoperative pain severity-specific distribution that an inpatient setting of 146 patients showed 90~% (134) reporting postoperative pain, distributed as ~20% slight, ~45% moderate, ~20% severe, and ~10% extreme. In an outpatient setting of 154 patients, ~80% (123) reported postoperative pain, with ~30% slight, ~40% moderate, ~25% severe, and ~4% extreme. By integrating these consolidated findings into our model, the rates were calibrated to be 25% for mild pain, 45% for moderate pain, and 30% for severe pain.

Postoperative Pain Management Drug Analysis & Competitive Landscape

The Postoperative Pain Management drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II-II clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Postoperative Pain Management treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Postoperative Pain Management therapeutics market.

Approved Therapies for Postoperative Pain Management

ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics

ZYNRELEF (formerly known as HTX-011) (bupivacaine and meloxicam) contains bupivacaine, a local amide anesthetic, and meloxicam, a NSAID, and is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 h after a bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. It is the first and only extended-release Dual-acting Local Anesthetic (DALA) and delivers 72 h of postoperative pain relief via a single needle-free application It received the US approval in 2021.

Postoperative Pain Management Pipeline Analysis

RizaFilm (rizatriptan): Gensco Pharma/IntelGenx

RizaFilm is a proprietary oral thin film formulation of rizatriptan benzoate. RizaFilm oral soluble film does not require a drink for swallowing and has ease of use, which facilitates rapid administration and relief from migraine symptoms. RizaFilm is an active ingredient that has been clinically proven to be effective for migraine-associated nausea, photophobia, and phonophobia

Postoperative Pain Management Key Players, Market Leaders and Emerging Companies

• Arthritis Innovation Corporation/Medincell
• Oculis
• PainReform
• Cali Biosciences
• Tris Pharma
• Neumentum
• Viatris, and others

Postoperative Pain Management Market Outlook

Postoperative pain is a common and expected acute outcome of surgery, and effective pain control is critical for optimal recovery and overall quality of care. However, despite the availability of multiple treatment options, fewer than half of patients report adequate pain relief. Management typically involves a combination of pharmacological therapies-such as opioids, NSAIDs, acetaminophen, local anesthetics, and other adjuvants-and non-pharmacological approaches, including physical therapy, acupuncture, and cognitive-based interventions. Traditionally, opioids were the mainstay for moderate-to-severe pain; however, concerns regarding adverse effects and the ongoing opioid crisis have driven a shift toward multimodal analgesia (MMA). This approach combines agents with different mechanisms of action to enhance efficacy while reducing opioid reliance. Current clinical guidelines emphasize individualized, evidence-based pain management strategies, prioritizing balanced regimens that improve safety, minimize side effects, and support faster recovery, with newer delivery techniques further optimizing outcomes despite potential cost implications.

Recent Updates

• In February 2026, Formosa Pharmaceuticals entered into an exclusive licensing agreement with Arrotex Pharmaceuticals for exclusive rights for the commercialization of APP13007 (clobetasol propionate ophthalmic suspension 0.05%) across Australia and New Zealand.
• In March 2026, Tris Pharma debut data from its Phase III ALLEVIATE-1 and ALLEVIATE-2 studies evaluating the safety and efficacy of cebranopadol, an investigational therapy, for the treatment of moderate-to-severe acute pain in patients following abdominoplasty and bunionectomy surgery, respectively, at the American Academy of Pain Medicine (AAPM) 2026 PainConnect annual meeting.
• As per the Q4 and full year financial results of 2025, Oculis announced that the NDA submission of OCS-01 for post-ocular surgery is ready in the first quarter of 2025.

Postoperative Pain Management Drug Updates

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2026-2036, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Postoperative Pain Management (2022-2036 Forecast)

The postoperative pain management landscape comprises pharmacological therapies, multimodal analgesia approaches, and non-pharmacological interventions, each targeting different aspects of pain control, inflammation, and functional recovery.

• Pharmacological therapies: NSAIDs, opioids, acetaminophen, corticosteroids, and anesthetics form the backbone of postoperative pain management by targeting inflammation and nociceptive pathways, while adjuncts such as gabapentin and muscle relaxants enhance analgesic efficacy.
• Multimodal analgesia (MMA): Combines multiple drug classes (e.g., NSAIDs, opioids, ketamine, gabapentinoids) with regional anesthesia techniques such as nerve blocks and epidurals to provide synergistic pain relief while minimizing opioid use and associated side effects.
• COX inhibitors- COX inhibitors block the cyclooxygenase enzymes COX-1 and COX-2, which drive the synthesis of prostaglandins, key mediators of inflammation, pain, and fever. Meloxicam, a preferential COX-2 inhibitor, selectively targets the inducible isoform to reduce pro-inflammatory prostaglandins while minimizing gastrointestinal side effects. NTM-001, a continuous-infusion formulation of non-selective ketorolac, inhibits both COX isoforms to provide sustained analgesia for acute pain. Both agents operate through the COX pathway, ultimately lowering prostaglandin production to control pain and inflammation.

Pharmacological therapies remain the current standard of care, while multimodal and non-opioid approaches are driving innovation and shaping the future postoperative pain management landscape.

Postoperative Pain Management Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the postoperative pain management drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in postoperative pain management is expected to vary based on clinical positioning, mechanism of action, and stage of development. Recently approved targeted therapy such as suzetrigine (JOURNAVX) is projected to demonstrate relatively faster uptake, driven by its first-in-class HIF-2a inhibition, oral administration, and strong clinical need in advanced or unresectable disease. In contrast, pipeline candidate CPL-01 is expected to follow a moderate uptake trajectory, reflecting its investigational status and gradual adoption as clinical evidence emerges. Meanwhile, Meloxicam (MR-107A-02) is anticipated to show gradual uptake.

Postoperative Pain Management Therapies Price Scenario & Trends

Pricing and analogue assessment of postoperative pain management therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Postoperative Pain Management

To keep up with Postoperative Pain Management market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the postoperative pain management emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in postoperative pain management, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at country level. Centers such as the University of Iowa, Stanford University School of Medicine, and McGovern Medical School etc. were contacted.Their opinion helps understand and validate current and emerging postoperative pain management therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in postoperative pain management.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Postoperative Pain Management, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of Postoperative Pain Management, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Postoperative Pain Management market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Postoperative Pain Management market.

Report Insights

• Postoperative Pain Management Patient Population Forecast
• Postoperative Pain Management Therapeutics Market Size
• Postoperative Pain Management Pipeline Analysis
• Postoperative Pain Management Market Size and Trends
• Postoperative Pain Management Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Postoperative Pain Management Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Postoperative Pain Management Treatment Addressable Market (TAM)
• Postoperative Pain Management Competitive Landscape
• Postoperative Pain Management Major Companies Insights
• Postoperative Pain Management Price Trends and Analogue Assessment
• Postoperative Pain Management Therapies Drug Adoption/Uptake
• Postoperative Pain Management Therapies Peak Patient Share Analysis

Report Assessment

• Postoperative Pain Management Current Treatment Practices
• Postoperative Pain Management Unmet Needs
• Postoperative Pain Management Clinical Development Analysis
• Postoperative Pain Management Emerging Drugs Product Profiles
• Postoperative Pain Management Market attractiveness
• Postoperative Pain Management Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the postoperative pain management market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of postoperative pain management?
• What are the disease risks, burdens, and unmet needs of postoperative pain management ? What will be the growth opportunities across the 7MM concerning the patient population with postoperative pain management?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of postoperative pain management? What are the current guidelines for treating postoperative pain management in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the postoperative pain management market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Key Conferences And Meetings
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. Postoperative Pain Management Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share (%) Distribution of Postoperative Pain Management by Therapy in 2025
• 6.3. Market Share (%) Distribution of Postoperative Pain Management by Therapy in 2036

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Difference between Acute and Chronic Pain
• 7.3. The Transition of Acute pain to Chronic Pain
• 7.4. Types of Acute Pain
• 7.5. Signs and Symptoms
• 7.6. Causes
• 7.7. Pathophysiology of Acute Pain
  • 7.7.1. Effects on Key Target Organs
• 7.8. Diagnosis
  • 7.8.1. Pain Scales used for Assessment of Pain
  • 7.8.2. Diagnostic Algorithm
• 7.9. Treatment
  • 7.9.1. Non-pharmacological Treatments for Postoperative Pain Management
  • 7.9.2. Pharmacological Treatments of Postoperative Pain Management

8. Treatment Guidelines

• 8.1. Postoperative Pain Management in Non-traumatic Emergency General Surgery: WSES-GAIS-SIAARTI-AAST Guidelines
• 8.2. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists Committee on Regional Anesthesia, Executive Committee, and Administrative Council (2017)

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: 7MM
• 9.3. Epidemiology in the United States
  • 9.3.1. Total Incident Cases of Postoperative Pain in the United States (2022-2036)
  • 9.3.2. Severity-specific Incident Cases of Postoperative Pain in the United States (2022-2036)
  • 9.3.3. Total Treated Pool of Postoperative Pain in the United States (2022-2036)
• 9.4. Epidemiology in EU4 and the UK
  • 9.4.1. Total Incident Cases of Postoperative Pain in EU4 and the UK (2022-2036)
  • 9.4.2. Severity-specific Incident Cases of Postoperative Pain in EU4 and the UK (2022-2036)
  • 9.4.3. Total Treated Pool of Postoperative Pain in EU4 and the UK (2022-2036)
• 9.5. Epidemiology Scenario in Japan
  • 9.5.1. Total Incident Cases of Postoperative Pain (2022-2036)
  • 9.5.2. Severity-specific Incident Cases of Postoperative Pain in Japan (2022-2036)
  • 9.5.3. Total Treated Pool of Postoperative Pain in Japan (2022-2036)

10. Patient Journey of Postoperative pain

11. Marketed Therapies

• 11.1. Key Cross of Marketed Drug
• 11.2. JOURNAVX (suzetrigine): Vertex Pharmaceuticals
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Safety and Efficacy
  • 11.2.6. Analyst View
• 11.3. ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Analyst View
• 11.4. COMBOGESIC (acetaminophen and ibuprofen) IV: Hyloris Pharmaceuticals, AFT Pharmaceuticals/Hikma Pharmaceuticals
  • 11.4.1. Product Description
  • 11.4.2. Regulatory Milestones
  • 11.4.3. Other Developmental Activities
  • 11.4.4. Summary of Pivotal Trials
  • 11.4.5. Safety and Efficacy
  • 11.4.6. Analyst View

12. Emerging Drugs

• 12.1. Key Cross Competition
• 12.2. CPL-01: Cali Biosciences
  • 12.2.1. Product Description
  • 12.2.2. Other Development Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trial Information
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Analyst View
• 12.3. PRF-110: PainReform
  • 12.3.1. Product Description
  • 12.3.2. Other Development Activities
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trial Information
  • 12.3.4. Safety and Efficacy
  • 12.3.5. Analyst View
• 12.4. OCS-01: Oculis Pharma
  • 12.4.1. Product Description
  • 12.4.2. Other Development Activities
  • 12.4.3. Clinical Development
    • 12.4.3.1. Clinical Trial Information
  • 12.4.4. Safety and Efficacy
  • 12.4.5. Analyst View

13. Postoperative Pain Management: 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Conjoint Analysis
• 13.4. Key Market Forecast Assumptions
  • 13.4.1. Cost Assumptions and Rebates
  • 13.4.2. Pricing Trends
  • 13.4.3. Analogue Assessment
  • 13.4.4. Launch Year and Therapy Uptakes
• 13.5. Total Market Size of Postoperative Pain Management in the 7MM
• 13.6. The United States
  • 13.6.1. Total Market Size of Postoperative Pain Management in the United States
  • 13.6.2. Total Market Size of Postoperative Pain Management by Therapies in the United States
• 13.7. EU4 and the UK
  • 13.7.1. Total Market Size of Postoperative Pain Management in EU4 and the UK
  • 13.7.2. Total Market Size of Postoperative Pain Management by Therapies in EU4 and the UK
• 13.8. Japan
  • 13.8.1. Total Market Size of Postoperative Pain Management in Japan
  • 13.8.2. Total Market Size of Postoperative Pain Management by Therapies in Japan

14. Unmet Needs of Postoperative Pain Management

15. SWOT Analysis of Postoperative Pain Management

16. KOL Views of Postoperative Pain Management

17. Market Access and Reimbursement of Postoperative Pain Management

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight